Clinical trials: Myositis
Rheumatic Diseases, Arthritis
Pain-Sleep in Rheumatic Disease
Overall, our understanding of how pain and sleep are experienced and how they can be treated in teenagers with rheumatic diseases is limited.
- Conditions
- Rheumatic Diseases, Arthritis, Lupus, Lupus Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07775612
- Testing
- Better Nights, Better Days for Youth
- Volunteers
- 43 people
- Sponsor
- The Hospital for Sick Children
Fibrodysplasia Ossificans Progressiva
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally…
- Trial name
- FOPal (NCT06089616)
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Ipsen
System Lupus Erythematosus, Systemic Sclerosis (SSc)
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
This study primarily involves the use of BCT301, an anti-CD19 Chemically induced pluripotent stem cell (CiPSC)-derived CAR-iT cells, for the treatment of patients with refractory autoimmune diseases, aiming to evaluate its…
- Conditions
- System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome
- Trial name
- NCT07301164
- Testing
- BCT301
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: The study duration will be a minimum of 180…
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Trial name
- TITAN (NCT06916806)
- Testing
- AZD5492
- Where
- 38 sites in United States, Canada and 8 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Dermatomyositis, Polymyositis
Methimazole to Treat Polymyositis and Dermatomyositis
This study will test the safety and effectiveness of the drug methimazole in treating polymyositis and dermatomyositis-inflammatory muscle diseases causing weakness and muscle wasting.
- Trial name
- NCT00001421
- Testing
- methimazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Interstitial Lung Disease, Myopathy, Inflammatory
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
There is likely a role for using anti-fibrotic medications in patients with myositis-associated interstitial lung disease (MA-ILD) to slow down disease progression, especially in patients who have fibrotic and progressive…
- Trial name
- NCT05335278
- Testing
- Nintedanib 150 milligrams [Ofev]
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
In the Netherlands, the human Papillomavirus (HPV) vaccination will be added to the National Vaccination Program for girls to protect against the development of cervical cancer.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomyositis
- Trial name
- HPV-kind (NCT00815282)
- Testing
- Human papilloma virus vaccine (cervarix)
- Where
- 3 sites in Netherlands
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- N.M. Wulffraat
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Inflammatory Myopathies, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06821659
- Testing
- anti-CD19 CAR-T cells
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Trial name
- NCT06479863
- Testing
- Pozelimab/Cemdisiran
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center
Autoimmune Diseases, Sickle Cell Disease
Microvascular and Fibrosis Imaging Study
In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical Coherence Tomography (OCT) will be used to assess…
- Conditions
- Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
- Trial name
- NCT01758250
- Testing
- Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Duke University
Polymyositis, Dermatomyositis
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group.
- Trial name
- NCT07122648
- Testing
- PN-101
- Where
- 5 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Paean Biotechnology Inc.
Atrial Remodeling, Myocardial Dysfunction
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure…
- Conditions
- Atrial Remodeling, Myocardial Dysfunction, Left Ventricular Remodeling, Left Ventricular Diastolic Dysfunction
- Trial name
- PARABLE (NCT04687111)
- Testing
- Sacubitril-Valsartan, Valsartan
- Where
- 2 sites in Ireland
- Volunteers
- 250 people
- Sponsor
- Mark Ledwidge
Dermatomyositis
Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study
The purpose of the study is to evaluate the effectiveness and safety of human immunoglobulin SCIg in the form of Hizentra (Immune globulin Subcutaneous) in patients with Dermatomyositis.
- Trial name
- NCT02271165
- Testing
- Immunoglobulin (Hizentra)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Thomas Jefferson University
Sporadic Inclusion Body Myositis
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis.
- Trial name
- NCT02573467
- Testing
- Bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Dermatomyositis, Polymyositis
Study and Treatment of Inflammatory Muscle Diseases
This study of inflammatory muscle diseases-polymyositis and dermatomyositis and related disorders-will examine what causes these diseases and describe the clinical features (signs and symptoms) associated with them.
- Trial name
- NCT00001265
- Where
- United States
- Volunteers
- 1,325 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis
Basiliximab Treating Interstitial Pneumonia of CADM
This is a 52-week, randomized, open and routine treatment controlled study. This study will assess the safety and efficacy of basiliximab as an add-on treatment for interstitial pneumonia in clinical amyopathic dermatomyositis…
- Trial name
- NCT03192657
- Testing
- Basiliximab, Calcineurin Inhibitors, Steroids
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Dermatomyositis
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
The goal of this clinical trial is to characterize to understand the effects of a type of cell therapy called Chimeric Antigen Receptor T lymphocyte (CAR T) therapy in adult patients with the autoimmune disease dermatomyositis.
- Trial name
- NCT06298019
- Testing
- KYV-101
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Rheumatic Diseases, Pediatric ALL
Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire
No tool has been found to evaluate behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric ALL, Children, Only
- Trial name
- NCT06460766
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
Myositis, Interstitial Lung Disease
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
- Trial name
- ATtackMy-ILD (NCT03215927)
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Rohit Aggarwal, MD
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.